Listen to leading experts discuss the new Scientific Statement from the American Heart Association, “Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease,” where two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.
Podden och tillhörande omslagsbild på den här sidan tillhör American Heart Association and American Diabetes Association. Innehållet i podden är skapat av American Heart Association and American Diabetes Association och inte av, eller tillsammans med, Poddtoppen.
